WO2002079467A3 - Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens - Google Patents

Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens Download PDF

Info

Publication number
WO2002079467A3
WO2002079467A3 PCT/DK2002/000208 DK0200208W WO02079467A3 WO 2002079467 A3 WO2002079467 A3 WO 2002079467A3 DK 0200208 W DK0200208 W DK 0200208W WO 02079467 A3 WO02079467 A3 WO 02079467A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibiotic
antisense molecules
growth
selection
transformed
Prior art date
Application number
PCT/DK2002/000208
Other languages
English (en)
Other versions
WO2002079467A2 (fr
Inventor
Peter E Nielsen
Liam Good
Original Assignee
Univ Koebenhavn
Peter E Nielsen
Liam Good
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Koebenhavn, Peter E Nielsen, Liam Good filed Critical Univ Koebenhavn
Publication of WO2002079467A2 publication Critical patent/WO2002079467A2/fr
Publication of WO2002079467A3 publication Critical patent/WO2002079467A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau procédé permettant de sélectionner des cellules génétiquement modifiées sans antibiotiques. On a découvert que des molécules antisens ciblées vers un gène cellulaire essentiel inhibe la croissance et sont appropriées comme agent de sélection de croissance de cellules transformées à l'aide d'un plasmide portant une version altérée dudit gène essentiel. Les résultats obtenus montrent qu'on peut utiliser des molécules antisens pour sélectionner des microbes transformés désirés contre un gène microbien essentiel sans antibiotique. Cette technologie est utilisée en génie génétique pour la recherche de croissance et d'isolation d'organismes transformés, et pour la maintenance de la croissance industrielle de ces organismes transformés, par exemple, dans la production de protéines mises au point par génie génétique utilisée comme alternative environnementale plus sure par rapport aux méthodes des sélection traditionnelles à base d'antibiotiques.
PCT/DK2002/000208 2001-03-29 2002-03-26 Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens WO2002079467A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100523 2001-03-29
DKPA200100523 2001-03-29

Publications (2)

Publication Number Publication Date
WO2002079467A2 WO2002079467A2 (fr) 2002-10-10
WO2002079467A3 true WO2002079467A3 (fr) 2004-03-04

Family

ID=8160404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000208 WO2002079467A2 (fr) 2001-03-29 2002-03-26 Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens

Country Status (1)

Country Link
WO (1) WO2002079467A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092736A2 (fr) * 2002-05-01 2003-11-13 Pantheco A/S Conjugues comportant des acides nucleiques peptidiques
GB0327056D0 (en) 2003-11-20 2003-12-24 Cobra Biolog Ltd Plasmid maintenance
EP1607482A1 (fr) * 2004-06-16 2005-12-21 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Procédé de sélection des cellules eucaryotiques transformées à base d'ARNi
ATE510914T1 (de) * 2004-07-02 2011-06-15 Avi Biopharma Inc Antisinn antibakterielle verfahren und verbindungen
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US7790694B2 (en) 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
DE102007036128A1 (de) 2007-07-23 2009-02-12 Universität Leipzig Antibiotische Peptide
WO2010014090A1 (fr) * 2008-07-30 2010-02-04 Michael Strathmann Procédés pour le ciblage de gènes
DE102009007381A1 (de) 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
EP2218781A1 (fr) 2009-02-11 2010-08-18 Qiagen GmbH Système de sélection à base d'ARNi
CN107353317A (zh) 2010-05-28 2017-11-17 萨勒普塔医疗公司 具有修饰的亚基间键和/或端基的寡核苷酸类似物
WO2012031243A2 (fr) 2010-09-03 2012-03-08 Avi Biopharma, Inc. Molécules d'arnds comportant des analogues oligonucléotidiques ayant des liaisons entre sous-unités et/ou des groupes terminaux modifiés
GB201117538D0 (en) 2011-10-11 2011-11-23 Royal Veterinary College The Methods
WO2013064633A1 (fr) 2011-11-04 2013-05-10 Amp-Therapeutics Gmbh Dérivés du peptide oncopeltus en tant que peptides antimicrobiens
WO2013074834A1 (fr) 2011-11-18 2013-05-23 Sarepta Therapeutics, Inc. Oligonucléotides fonctionnellement modifiés et sous-unités associées
EP2791341A4 (fr) * 2011-12-12 2015-07-29 Chuanxin Sun Utilisation d'oligonucléotides en biologie végétale
CN104411831B (zh) 2012-03-20 2020-08-11 萨勒普塔医疗公司 寡核苷酸类似物的硼酸缀合物
US10227661B2 (en) 2014-11-21 2019-03-12 GeneWeave Biosciences, Inc. Sequence-specific detection and phenotype determination
EP3302489A4 (fr) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. Procédés et composés pour le traitement de maladies et d'états pathologiques associés aux lymphocytes
CN114958896B (zh) * 2021-11-12 2023-06-27 淮阴师范学院 一种提高乳酸片球菌的电转化效率的方法
WO2023093960A1 (fr) * 2021-11-26 2023-06-01 Syddansk Universitet Conjugué peptide-oligonucléotide modifié

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723292A (en) * 1984-05-25 1998-03-03 Zymogenetics, Inc. Stable DNA constructs
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO1999013893A1 (fr) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Acides nucleiques peptidiques a activite antibacterienne
WO2000044906A2 (fr) * 1999-01-27 2000-08-03 Elitra Pharmaceuticals, Inc. Genes identifies intervenant dans la proliferation cellulaire d'escherichia coli
WO2001027261A2 (fr) * 1998-11-11 2001-04-19 Pantheco A/S Conjugues entre un peptide et un analogue d'acide nucleique tel que anp, anl ou une morpholine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723292A (en) * 1984-05-25 1998-03-03 Zymogenetics, Inc. Stable DNA constructs
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO1999013893A1 (fr) * 1997-09-16 1999-03-25 Isis Pharmaceuticals, Inc. Acides nucleiques peptidiques a activite antibacterienne
WO2001027261A2 (fr) * 1998-11-11 2001-04-19 Pantheco A/S Conjugues entre un peptide et un analogue d'acide nucleique tel que anp, anl ou une morpholine
WO2000044906A2 (fr) * 1999-01-27 2000-08-03 Elitra Pharmaceuticals, Inc. Genes identifies intervenant dans la proliferation cellulaire d'escherichia coli

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DOYLE DF. ET AL.: "Inhibition of gene expression inside cells by peptide nucleic acids: effect of mRNA target sequence, mismatched bases, and PNA length.", BIOCHEMISTRY 2001 JAN 9;40(1):53-64., XP002187945 *
GOOD LIAM ET AL: "Bactericidal antisense effects of peptide-PNA conjugates.", NATURE BIOTECHNOLOGY, vol. 19, no. 4, April 2001 (2001-04-01), pages 360 - 364, XP002187946, ISSN: 1087-0156 *
HANCOCK R E: "Peptide antibiotics", LANCET THE, vol. 349, no. 9049, 8 February 1997 (1997-02-08), pages 418 - 422, XP004246070, ISSN: 0140-6736 *
LARSEN H J ET AL: "Antisense properties of peptide nucleic acid", BIOCHIMICA ET BIOPHYSICA ACTA. GENE STRUCTURE AND EXPRESSION, vol. 1489, no. 1, 10 December 1999 (1999-12-10), pages 159 - 166, XP004275530, ISSN: 0167-4781 *
MARTTI VAARA ET AL: "Group of Peptides That Act Synergistically with Hydrophobic Antibiotics against Gram-Negative Enteric Bacteria", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 8, no. 40, 1996, pages 1801 - 5, XP002080197, ISSN: 0066-4804 *
NIELSEN PE. ET AL.: "Peptide nucleic acids as antibacterial agents via the antisense principle.", EXPERT OPIN INVESTIG DRUGS 2001 FEB;10(2):331-41., XP001052987 *

Also Published As

Publication number Publication date
WO2002079467A2 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
WO2002079467A3 (fr) Selection de souche bacterienne sans antibiotique a l'aide de molecules antisens
Wang et al. Expanding targeting scope, editing window, and base transition capability of base editing in Corynebacterium glutamicum
Mao et al. Versatile aromatic compound-degrading capacity and microdiversity of Thauera strains isolated from a coking wastewater treatment bioreactor
Suntornsuk et al. Purification and characterisation of keratinase from a thermotolerant feather-degrading bacterium
WO2004076659A3 (fr) Procede de preparation de microorganismes evolues permettant la creation ou la modification de voies metaboliques
AU2002319281A1 (en) Process for the preparation of l-amino acids using strains of the enterobacteriaceae family which contain an enhanced pykf gene
DE60226979D1 (en) Biofungizide
WO2006020663A3 (fr) Production de succinate aerobie dans des bacteries
DK2067864T3 (da) Fremgangsmåde til frembringelse af L-lysin ved anvendelse af Escherichia coli
ATE330022T1 (de) Verfahren zur herstellung einer zielsubstanz durch fermentation
WO2002081698A3 (fr) Procede de production d'acides amines l a l'aide de souches de la famille des enterobacteriaceae qui contiennent un gene frur attenue
Zhao et al. Multiplex gene editing and large DNA fragment deletion by the CRISPR/Cpf1-RecE/T system in Corynebacterium glutamicum
Ramirez et al. Kinetic study of penicillin acylase production by recombinant E. coli in batch cultures
Zhang et al. CRISPR/Cas13d-mediated microbial RNA knockdown
Zhang et al. Complete genome sequence of Alcaligenes faecalis strain JQ135, a bacterium capable of efficiently degrading nicotinic acid
TW200634151A (en) Transformant expressing nitrile hydratase
Pogorelova et al. Cobalt-dependent transcription of the nitrile hydratase gene in Rhodococcus rhodochrous M8
WO2007120198A3 (fr) Matériaux et procédés de production améliorée de composés organiques
BR0010817A (pt) Processo para a preparação fermentativa de l-aminoácidos com amplificação do gene gnd
JP2011200133A (ja) 遺伝的に改変された微生物の製造方法
Buchholz et al. Transfer of plasmids to an antibiotic-sensitive mutant of Zymomonas mobilis
WO2007018744A3 (fr) Biosynthese sans cellule d'acide nucleique
ATE443144T1 (de) Neue, gegenüber halogenverbindungen tolerante formiatdehydrogenase und verfahren zur herstellung davon
WO2003046156A3 (fr) Biomasses bacteriennes, leur protocole d'obtention, et leur utilisation pour la bacterisation de sols et de residus de cultures
Kuddus et al. Purification and properties of cold-active metalloprotease from Curtobacterium luteum and effect of culture conditions on production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP